The risk of neutropenia and leukopenia in advanced non-small cell lung cancer patients treated with erlotinib: a prisma-compliant systematic review and meta-analysis
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a critical
member of systemic therapy for advanced non-small-cell lung cancer (NSCLC). Erlotinib is …
member of systemic therapy for advanced non-small-cell lung cancer (NSCLC). Erlotinib is …
Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review
X Li, H Yang, J Zhao, H Gao - OncoTargets and therapy, 2015 - Taylor & Francis
Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR)
mutation. As a consequence, targeted therapy based on screening of tyrosine-kinase …
mutation. As a consequence, targeted therapy based on screening of tyrosine-kinase …
Erlotinib in non-small cell lung cancer: from a thought to necessity
Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer,
which is the leading cause of death worldwide with the majority of patients presenting with …
which is the leading cause of death worldwide with the majority of patients presenting with …
[PDF][PDF] Expression of thioredoxin reductase-1 and its effect in non-small cell lung cancer
DM Ran, QW Zhang, HL Su, C Wang, FH Gao - Int. J. Clin. Exp. Med, 2016 - e-century.us
Objective: We detected the expression of thioredoxin reductase-1 (TrxR1) in non-small cell
lung cancer (NSCLC) and the effect of TrxR1 silencing in NSCLC. Method: TrxR1 …
lung cancer (NSCLC) and the effect of TrxR1 silencing in NSCLC. Method: TrxR1 …